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Numerous conditions promote oxidative stress, leading to the build-up of reactive aldehydes that cause cell damage and contribute to
cardiac diseases. Aldehyde dehydrogenases (ALDHs) are important enzymes that eliminate toxic aldehydes by catalysing their oxidation
to non-reactive acids. The review will discuss evidence indicating a role for a speciﬁc ALDH enzyme, the mitochondrial ALDH2, in combating
oxidative stress by reducing the cellular ‘aldehydic load’. Epidemiological studies in humans carrying an inactive ALDH2, genetic models in
mice with altered ALDH2 levels, and small molecule activators of ALDH2 all highlight the role of ALDH2 in cardioprotection and suggest a
promising new direction in cardiovascular research and the development of new treatments for cardiovascular diseases.
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This article is part of the Review Focus on: ‘Mitochondria in Cardiac Disease: Emerging Concepts and Novel Therapeutic
Targets’.
1. Introduction: oxidative stress
and aldehyde toxicity
Ischaemia and reperfusion as well as mismatch between cardiac
demand and cardiac function result in oxidative stress in the myocar-
dium.
1,2 Oxidative stress is a state in which excessive reactive oxygen
species (ROS), such as O2
− and H2O2, accumulate and result in cel-
lular toxicity, due to imbalance between production and removal of
ROS.
3,4 In the myocardium, a signiﬁcant ROS production occurs in
the mitochondria and when it is excessive, it contributes to oxidative
stress and mitochondrial dysfunction.
5,6 The need to reduce oxidative
stress to protect the heart led to both preclinical and clinical research.
Although early research efforts focused on the deleterious effects of
ROS in the myocardium,
1,7 more recent work revealed that accumu-
lation of cytotoxic and reactive aldehydes derived from ROS-induced
stress
8–10 or from direct insults of exogenous aldehydes
11 can also
severely impair cardiac functions. Although low levels of ROS and
aldehydes may be regarded as second messengers that trigger
stress-activated anti-oxidant mechanisms (review by Poli et al.
12), it
is nevertheless critical that the cells maintain a defensive capacity to
prevent acute or chronic build-up of excessive oxidative stress and
toxic aldehydes, as these cause irreversible injuries.
Aldehydes are generated during numerous physiological processes
including catabolism of amino acids, transmitters such as GABA,
serotonin, noradrenaline, adrenaline, and dopamine.
13–15 Further,
more than 200 different aldehydes are generated through lipid metab-
olism
16 and metabolism of carbohydrates also generates many aldehy-
dic intermediates.
13 In addition to these endogenous aldehydes,
aldehydes are ubiquitously present in the environment in smog, ciga-
rette smoke, motor vehicle exhaust, and in a variety of industrial pro-
cesses including the production of polyurethane, polyester plastics
(these include formaldehyde, acetaldehyde, and acrolein). Although
some dietary and aromatic aldehydes (e.g. citral, cinnamaldehyde, ben-
zaldehyde, and retinal) are approved additives in various foods and
cosmetics where they impart ﬂavour and odour, many others are
cytotoxic. A mechanism for a rapid clearance of aldehydes is essential
to protect the human body, in general, and the myocardium and the
brain, in particular, from the harmful effects of these aldehydes.
Aldehydes are diffusible and highly reactive agents in cells; they
form adducts with lipids, proteins, and DNA, which affect the function
of these macromolecules and can lead to their inactivation.
16 Because
of DNA damage induced by aldehyde adducts, a wide range of alde-
hydes have been classiﬁed as mutagenic and carcinogenic. These
include even acetaldehyde, which is derived from ethanol drinking;
excessive ethanol consumption has been linked to alcoholic liver dis-
eases and various upper aerodigestive and gastrointestinal cancers.
17
2,4-Dihydroxy-phenyacetaldehyde, another highly potent neurotoxin,
is an intermediate of dopamine metabolism and has been implicated
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18,19 Methylglyoxal, an aldehyde accu-
mulated in hyperglycaemia, is a key intermediate for the adduction
formation in advanced glycation end-products found in various
organs of diabetic patients.
20 Many other reactive and cytotoxic alde-
hydes have been shown to be associated with other diseases.
Of particular interest to cardiovascular diseases are reactive alde-
hydes such as 4-hydroxy-2-nonenal (4-HNE) and malondialdehyde
(MDA).
21 In conditions like ischaemia and reperfusion, ROS-induced
peroxidation of polyunsaturated fatty acids like linoleic acid and ara-
chidonic acid present in the plasma membrane leads to 4-HNE pro-
duction
16,22 (Figure 1). 4-HNE is a highly reactive carbonyl
compound due to the presence of a,b-unsaturated carbons.
23
4-HNE readily reacts with cysteine, histidine, and lysine residues,
and thus forms protein adducts via the Michaels addition.
23,24
4-HNE adduct formation in the myocardium has been shown to
lead to the inhibition of key metabolic enzymes such as glyceralde-
hyde 3-phosphate dehydrogenase
24 and the 26S proteosome,
25,26
thus leading to further accumulation of damaged proteins in the
cell. 4-HNE also impairs ATP-generating ability in the mitochondria,
27
induces opening of mitochondria permeability transition pore, and
impairs mitochondrial integrity in a concentration-dependant and
calcium-mediated manner
28,29 (Figure 1), thus reducing the cell’s
ability to repair the damaged macromolecules. As a potent cardiac
cytotoxin, 4-HNE has been shown to directly inhibit contractility,
30
induce pro-arrhythmic effects in isolated cardiac myocytes,
31 and
cause tissue damage after cardiac ischaemia.
32
In another study of aldehyde-induced cardiac toxicity, Wang et al.
11
showed that acrolein, an exogenous reactive aldehyde that is ubiqui-
tously present in many food sources, can exacerbate ischaemic
damage to the heart. In a model of acute myocardial infarction
(AMI), oral delivery of acrolein (5 mg/kg) to mice 30 min before cor-
onary artery occlusion and 24 h reperfusion produced a signiﬁcantly
increased myocardial infarct size when compared with the water-
treated control group.
11 Interestingly, acrolein also abolished the
late preconditioning cardioprotective effect offered by the pre-
treatment of an NO donor, diethylenetriamine/NO. The levels of
acrolein–1PKC adducts and acrolein adducts in other proteins in
the mitochondrial fraction increased in an acrolein dose-dependent
Figure 1 A scheme depicting aldehyde-induced mitochondrial damage and how ALDH2 reduces this aldehydic toxicity. (Left) Ischaemia and reper-
fusion and other oxidative stress in the heart increase ROS production, which triggers lipid peroxidation and the accumulation of reactive aldehydes,
such as 4-HNE. Other xenogenic aldehydes from the environment, from ethanol metabolism, and from food additives can also increase the cellular
‘aldehydic load’ (depicted as a grey cloud in the ﬁgure). Aldehydes induce inactivation of a number of macromolecules including the proteasome, the
electron transport chain (ETC) in the mitochondria, as well as inactivation of ALDH2 itself. This aldehyde-induced macromolecule inactivation con-
tributes to mitochondrial impairment and increases in oxidative stress, thus leading to cell damage. Particularly relevant to cardiac disease, the use of
nitroglycerin (GTN) can further contribute to ALDH2 inactivation, thus decreasing the cell’s natural ability to reduce ROS-induced aldehydic load and
cytotoxicity. Finally, a common mutation in ALDH2 (ALDH2*2) in humans further impairs the ability to reduce the aldehydic load under oxidative
stress conditions. (Right) Agents that increase ALDH2 activity and protect ALDH2 from inactivation by aldehydes and by GTN will decrease the
aldehydic load by enhancing the conversion of aldehydes to non-reactive acid (blue cloud in the scheme), thus leading to cytoprotection. Such
one potential agent is Alda-1, an aldehyde dehydrogenase 2 activator. Alda-1 increases ALDH2 activity by about two-folds, blocks ALDH2 inactivation
by both aldehydes and GTN, and thus increases the cell’s natural ability to protect from oxidative stress, leading to 60% reduction from cardiac
damage in an animal model of AMI. The ability of Alda 1 to increase the activity of the mutant ALDH2*2 may be of particular importance for
over .0.5 billion humans who carry this mutation. (See text for details.) Reduction in aldehydic load decreases mitochondrial structural and functional
damages and increases ATP generation, thus leading to cardiac protection from oxidative stress.
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11 High cardiovascular toxicity and statistically signiﬁcant
association between aldehyde-containing components of polluted
air or cigarette smoke and incidents of ischaemic heart disease,
arrhythmias, and heart failure have also been reported.
31 These ﬁnd-
ings heightened the importance and awareness that both endogenous
reactive aldehydes such as 4-HNE and aldehydes present as environ-
mental pollutants might be contributors of these harmful cardiovascu-
lar effects and that a mechanism that protects from these aldehydes
and accelerates their removal is essential to protect the myocardium
as well as other organs from oxidative stress.
2. Aldehyde dehydrogenases
There is a class of detoxifying enzymes that catalyse the removal of
aldehydes in the body. These are the NAD(P)
+-dependent aldehyde
dehydrogenase (ALDH) super gene family. Nineteen ALDH genes
have been mapped in the human genome, of which 17 ALDH iso-
zymes are expressed with different tissue distributions.
15 All the
ALDH genes are nuclear encoded, but at least ﬁve ALDH isozymes
reside and function in the mitochondria.
13 We have focused this
review on the role of the mitochondrial ALDH2 in cardiovascular
disease, since this enzyme has emerged as a key enzyme of cardiopro-
tection.
8,9,33–35
ALDH2 is a tetrameric enzyme and is expressed abundantly in the
liver and lung, and is also present in organs that require high mito-
chondrial capacity for oxidative ATP generation such as heart and
brain.
36 ALDH2 is important in the oxidization of aldehydic sub-
strates, such as 4-HNE, acrolein, and short chain, aromatic or polycyc-
lic carbons.
23,37 In addition to its dehydrogenase activity, ALDH2 can
function as an esterase and reductase, depending on the substrates.
Much current attention has also been drawn to ALDH2 for its role
in the biotransformation of nitroglycerin, by its reductase activity, to
1,2-glyceryl dinitrate for the production of nitric oxide, a critical
vasodilator.
38,39
ALDH2 is best known for its ability as a detoxifying enzyme of acet-
aldehyde, an intermediate of ethanol metabolism. Importantly, more
than 40% of the East Asians population carries a common
ALDH2*2 mutant allele, which results in a dramatic reduction in
the enzymatic activity when compared with the ALDH2*1, wild-type
allele;
40 carrier of this mutant ALDH2 has a characteristic
acetaldehyde-induced facial ﬂushing when drinking alcohol. The
mutation is caused by a single-nucleotide substitution (G to A) in
exon 12, leading to a change from glutamate to lysine at position
487.
41 The biochemical characterization, molecular structure, and
physiological consequences of ALDH2*2 have been extensively
studied.
41,42 The E487K amino acid substitution at the dimer interface
of the tetrameric enzyme resulted in disruption of the co-enzyme
NAD binding and reduced catalytic activity of ALDH2*2.
43 Heterozy-
gous ALDH2*1/*2 individuals retain only 10–45% of the enzymatic
activity and homozygous ALDH*2/*2 individuals have 1–5% of wild-
type ALDH activity, due to this single amino acid polymorphism.
44
The ALDH2*2 allele has been linked to an increased risk of
oesophageal and other upper aerodigestive tract cancers among
alcohol drinkers.
45–47 But, higher incidences of insensitivity to
nitroglycerin treatment for angina,
48 MI,
49,50 hypertension,
51,52 and
other oxidative-related neurodegenerative diseases
14 have also been
associated with ALDH2*2 mutation in recent years (see further dis-
cussion in the following). Since the affected world population of
ALDH2*2 is estimated to be at least 540 million or  8% of the
world population,
45 it is warranted that health risk for cardiac diseases
be re-evaluated in ALDH2*2 carriers.
3. Mitochondrial ALDH2 and
cardioprotection against ischaemia
and reperfusion injury
AMI is one of the leading causes of disability and death in the USA.
53
Clinical interventions such as angioplasty or thrombolytic agents have
been effective in re-establishing the coronary ﬂow. However, treat-
ments to further reduce the injuries incurred during the ischaemic
period or by reperfusion are not available. A large body of research
has identiﬁed an endogenous process of cytoprotection from ischae-
mia/reperfusion injury.
54 Cytoprotection can be induced by subjecting
an organ to short bouts of ischaemia prior to the prolonged ischae-
mia, a process termed ischaemic preconditioning.
55 Preconditioning
can also be induced and/or enhanced by select hormones and neuro-
transmitters
56 and is dependent on the activation of the diacylgly-
cerol-dependent protein kinase C epsilon (1PKC
57,58).
One pharmacological agent that mimics ischaemic-preconditioning-
induced cardioprotection is ethanol.
59,60 This effect may be different
from the cardioprotective effect of moderate habitual consumption
of alcohol;
61 we found that a brief exposure to 10 mM ethanol
10–20 min prior to ischaemia can protect rat heart from prolonged
ischaemic damage in both cultured cardiac myocytes and adult
whole heart.
60 Using an unbiased proteomic approach, we then
identiﬁed the mitochondrial ALDH2 as a key enzyme downstream
of ethanol-induced 1PKC-dependent cardioprotection.
9 ALDH2 is
phosphorylated under conditions that lead to cardiac cytoprotection
and its enzymatic activity is inversely correlatedwith the severityof the
damage from cardiac ischaemia (R
2 ¼ 0.95
9). High-throughput screen-
ing of libraries of compounds identiﬁed N-(1,3-benzodioxol-
5-ylmethyl)-2,6-dichlorobenzamide (ALDH activator-1 or Alda-1,
MW ¼ 324) and its halogen analogues as selective agonists of ALDH2
(Figure 1).
The identiﬁcation of a selective activator for ALDH2 conﬁrmed
that ALDH2 activation is not only required, but sufﬁcient to
induce cardioprotection; treatment by Alda-1 increased ALDH2
activity by two-fold and reduced infarct size by 60% in an in vivo
model of myocardial infarction in rats. It is likely that the beneﬁt
of ALDH2 activation is to facilitate the removal of cytotoxic alde-
hydes, such as 4-HNE and others that accumulate during ischaemia
and reperfusion.
9,32,62,63 4-HNE has been shown to be a substrate as
well as a potent inhibitor of ALDH2 (due to 4-HNE adduct for-
mation on ALDH2
64,65). Using a human recombinant ALDH2
enzyme, at 100 mM, 4-HNE completely inactivated ALDH2 activity
in vitro. However, the 4-HNE-induced inhibition of ALDH2 activity
was completely prevented in the presence of Alda-1.
9 As antici-
pated, following ischaemia and reperfusion, the accumulation of
4-HNE–protein adducts was lower in hearts treated with Alda-1,
relative to vehicle-treated controls.
9 The ability of Alda-1 to
reduce cardiac damage is therefore likely due to a combination of
direct enzyme activation of ALDH2 and prevention of ALDH2 inac-
tivation by its reactive substrate, 4-HNE, which is formed and
accumulates under oxidative stress (Figure 1). Using an open-chest
model of AMI in vivo, Churchill et al.
33 further demonstrated that
under cardioprotective conditions, 1PKC translocates directly into
the mitochondria where it interacts with ALDH2, increases its
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JNK1/2 and ERK1/2 and reduced 4-HNE–protein adduct formation.
Further, in 1PKC knockout mice, direct activation of mitochondrial
ALDH2 by an Alda-1 analogue, Alda-44, protects the heart against
ischaemia/reperfusion injuries similar to what was achieved by
ethanol preconditioning in the wild-type mice.
66 These results indi-
cate that ALDH2 is a direct downstream substrate of 1PKC and
suggest that the activation of ALDH2 is necessary and sufﬁcient
to confer. Hill et al.
67 have shown that inhibition of 4-HNE oxidation
during ischaemia may be due to a decrease in NAD/NADH ratio,
which renders ALDH2 less effective. On the other hand, excessive
production of 4-HNE via lipid peroxidation occurs most likely
during the reperfusion period when NAD levels are rapidly
restored. It is during that reperfusion period that ALDH2 may
play a critical role in cardioprotection by enhancing the removal
of ROS-generated 4-HNE. We found that Alda-1 increases the
removal of 4-HNE to levels closer to basal levels
9 by increasing
the productive substrate–enzyme interaction.
68 Furthermore,
Beretta et al.
69 have recently demonstrated that Alda-1 also
increases the afﬁnity of ALDH2 for NAD, which should result in
increased ALDH2 activity even if NAD levels have not yet recov-
ered back to basal levels, and cardioprotection by enhancing the
detoxifying capability of the cells against reactive aldehydes.
Recent epidemiological studies indicated that ALDH2 is critical in
cardiovascular diseases. A study conducted in Korea showed an
association of higher risk of MI with the E487K mutation carried by
both ALDH*1/*2 heterozygous and ALDH2*2/*2 homozygous indi-
viduals in older Korean men.
49 An independent study conducted in
Japan also identiﬁed ALDH2*2/*2 genotype as a risk factor for MI inci-
dents in Japanese me.
50 An important feature of Alda-1 is its ability to
increase the activity of the inactive ALDH2*2 mutant.
9 Alda-1
increased the enzymatic activity of ALDH2*2 homotetramers and
ALDH2*2 heterotetramers by 11- and two-fold, respectively. The
ability of Alda-1 to partially complement or restore the activity of
the mutant, ALDH2*2, is striking, as it is rare to ﬁnd a small molecule
that can speciﬁcally rescue a mutation in humans. This enhancement
of catalytic activity translates to a possibility of rescuing some enzy-
matic activity for the ALDH2*2/*2 individuals and restoring the
activity of ALDH2*1/*2 individuals to almost the basal level in the
wild-type ALDH2*1/*1 individual.
9 Co-crystal structures of Alda-1
with both ALDH2*1 wild-type and ALDH2*2 mutant enzymes have
recently been resolved and offered detailed mechanistic explanations
on how Alda-1 can enhance the enzymatic activity, protect ALDH2
against 4-HNE inactivation, and restore the function of ALDH2*2
mutation.
68 Structural comparison revealed that Alda-1 interacts
with ALDH2 at the substrate-binding tunnel and kinetically increased
the rate of catalysis by reducing the probability of non-productive sub-
strate hydrolysis. The unique binding site of Alda-1 also positions this
compound as a shield to the key sulfhydryl amino acid, Cys302, at the
catalytic centre and likely protects the ALDH2 molecule against
enzyme inactivation by its reactive aldehyde, 4-HNE. Finally, even
though Alda-1 made no direct contact with the mutated E487K
residue, it nevertheless functioned as a molecular chaperone and
restored the electron density and structural abnormality of the
co-enzyme-binding site within ALDH2*2. Alda-1 therefore represents
as a new pharmacological agonist and opens the possibility that modu-
lation of ALDH2 by small molecule enzyme activators should have
therapeutic value for cardiovascular and other ALDH2-related
diseases.
4. Angina, nitroglycerin
bioactivation, tolerance,
and ALDH2
Since its discovery in 1860s, nitroglycerin has become one of the most
widely used drugs, treating patients with stable and unstable angina
and with AMI and heart failure. About 9.8 million Americans experi-
ence angina annually and many of them are given nitroglycerin for
both acute and chronic symptom relief.
70 The beneﬁcial effect of
nitroglycerin is achieved due to its ability to increase blood ﬂow to
the heart by dilating coronary arteries and decreasing cardiac
preload due to venodilation.
71 Although acute treatment including
sublingual regimen is immediate and effective, the beneﬁt of nitrogly-
cerin has been limited because of in vivo tolerance that rapidly devel-
ops on continuous treatment.
72 (Nitroglycerin tolerance is manifested
as a reduced vasodilatation effect and requirement of high doses of
the drug after continuous treatment.)
Previous experimental and clinical investigations have uncovered
several critical mechanisms of nitroglycerin tolerance, including oxi-
dative stress, endothelial dysfunction, and increased sensitivity to
vasocontrictors.
72,73 Recently, Chen et al. reported a pathway invol-
ving the mitochondrial enzyme, ALDH2, that provides a novel
mechanistic insight into the development of nitroglycerin toler-
ance.
38,39,74 In their study measuring conversion of nitroglycerin to
nitric oxide, ex vivo, they found that bioactivation of nitroglycerin
into 1,2-glyceral dinitrate, the physiologically relevant metabolite of
nitroglycerin, was signiﬁcantly diminished in aortas from ALDH2
knockout mice. Similar results were observed using ALDH2-selective
inhibitors in animals as well as in humans.
75,76 These studies have
deﬁned an unequivocal dependence of nitroglycerin bioactivation on
ALDH2. Further studies in murine and human tissues have demon-
strated a more targeted role for ALDH2 that explains nitroglycerin
tolerance
77,78 (Figure 1). In rabbit aorta made tolerant by large
doses of nitroglycerin, ALDH2 dehydrogenase activity was inhibited
by  50%.
74 Similar inhibition was observed in studies using rat
hearts, ex vivo.
9 Although it remains to be determined how prolonged
treatment with nitroglycerin leads to inactivation of ALDH2, these
studies have opened a new avenue for examining the role of
ALDH2 in the myocardium.
As described above, activation of ALDH2 reduced cardiac damage
caused by ischaemia insult, indicating a cardioprotective role for
ALDH2.
9 That study also demonstrated that inactivation of ALDH2
associated with nitroglycerin tolerance resulted in an increase in
infarct size.
9 These data suggest a potential risk to patients who
experience an AMI while on continuous nitroglycerin treatment
(Figure 1). Whereas clinical treatments such as the intermittent use
of organic nitrates have proven effective in reducing tolerance,
other consequences of nitroglycerin tolerance have been poorly
understood. Correlation studies analysing existing patients have
yielded useful but incomplete data. In a 5-year follow-up study exam-
ining the long-term efﬁcacy of nitrate therapy for the treatment of
AMI in Japan, Yamauchi et al. found higher mortality rate in nitrate-
treated group (18.9%), compared with the control patients (11.0%).
However, the author acknowledged the limitation of the study, as
the difference may be attributed to, among other uncontrolled
factors, an increased frequency of nitrate use in patients with more
severe conditions.
79 Information on the consequence of nitroglycerin
tolerance will be valuable for a better clinical use of nitroglycerin and
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vascular diseases.
In the light of the ALDH2-dependent bioactivation of nitroglycerin
in Asians carrying the E487K mutation, it is predicted that the substan-
tially diminished ALDH2 activity would lead to a decreased response
to nitroglycerin treatment. Indeed, in vitro experiments showed that
the E487K mutant enzyme was  10-fold slower in catalysing nitrogly-
cerin conversion to 1,2-glyceral dinitrate.
69 Moreover, previous clini-
cal studies conﬁrmed a marked decrease in nitroglycerin efﬁcacy in
patients carrying the mutant ALDH2*2 relatively to carriers of the
wild-type enzyme.
48,75 Not surprisingly, larger doses of nitroglycerin
were required to achieve sufﬁcient vasodilatation in subjects with
the ALDH2*2 form. Because the Asian ALDH2*2 mutation may be
associated with a higher risk of various diseases including ischaemic
damage
9,13 due to a signiﬁcant loss of ALDH2 activity, the conse-
quence of nitroglycerin tolerance in the background of E487K poly-
morphism needs to be further investigated.
Since Alda-1 activates both the dehydrogenase activity and esterase
activity of ALDH2,
9,68 Beretta et al. evaluated the effect of Alda-1 on
bioactivation of nitroglyercin.
69 Surprisingly, Alda-1 failed to increase
GTN denitration and bioactivation in these assays using either the
ALDH2 wild-type and ALDH2*2 recombinant enzyme in vitro.A
drug that can increase the potency of nitroglycerin either by enhan-
cing its bioconversion to NO and/or by preventing the inhibitory
effect of nitroglycerin on ALDH2 will clearly be beneﬁcial, especially
for the ALDH2*2 human subjects.
5. ALDH2 in transgenic mice,
ethanol/acetaldehyde metabolism,
and cardiovascular disease
Several independent ALDH2 transgenic mice have been established
and studied extensively, especially with regard to the role of
ALDH2 in ethanol metabolism. In one model, ALDH2 knockout
mice were produced by gene interruption at the ALDH2 locus.
80
As expected, these ALDH2-null mice lacked any detectable ALDH2
enzyme activity, accumulated a high level of acetaldehyde when
exposed to ethanol, and were signiﬁcantly more sensitive to alcohol
and acetaldehyde toxicity and damage.
81–83 Surprisingly, in these
ALDH2-null mice, both acute and chronic administration of ethanol
seem to produce a smaller extent of oxidative stress in the liver as
measured by the decreased levels of MDA, alanine aminotransferase,
TNF-a in the serum and increased level of the anti-oxidant, gluta-
thione, when compared with the wild-type ALDH mice.
84,85 The mol-
ecular mechanism for the reduction of these oxidative stress
biomarkers is not clear, but may be associated with the metabolism
of ethanol itself through the microsomal CYP2E1 pathway in the
liver. It appears unlikely, though, that such ethanol-induced protective
effect exists in hearts of the ALDH2*2 carriers. In fact, using the same
ALDH2-null mice, Wenzel et al.
86 demonstrated that the loss of
ALDH2 enzyme activity led to increased mitochondrial oxidative
stress in aortic endothelia by three pro-oxidant stimuli, nitroglycerin,
doxorubicin, and acetaldehyde (Figure 1).
Overexpression of ALDH2 wild-type enzymes appeared to confer
multiple beneﬁcial effects to the heart tissue and cardiac functions in
another transgenic mice model. Ma et al.
87 explored the effect of
ALDH2 overexpression on acute ethanol-induced myocardium
damage. Acute ethanol challenge (3 g/kg) severely impaired
myocardial and myocyte functions in the wild-type FVB mice as a
result of acetaldehyde toxicity. This is evidenced by the reduction
in maximal velocity of pressure development and decline (+dP/dt),
left ventricular developed pressure, cell shortening, prolonged
relengthening duration, and an increase in cardiac protein carbonyl
level within 24 h after ethanol administration. These negative out-
comes were much reduced in mice expressing four-fold higher
levels of ALDH2. In this study, overexpression of ALDH2 was associ-
ated with a suppression of phosphatase activity which leads to
enhanced Akt and AMP-activated protein kinase activities and regu-
lation of their downstream targets Foxo3 transcription factor and
caspase-3.
87,88 Thus, ALDH2 appears critical in protecting the heart
from aldehyde toxicity and is able to elicit signalling events that can
protect against myocardial damages caused by acute ethanol toxicity.
Acetaldehyde toxicity also results in an exacerbated cardiac hyper-
trophy and contractile defect.
89,90 In models of chronic alcohol inges-
tion, mimicking human alcoholism, overexpression of the ALDH2
enzyme dramatically reduced the complications of the cardiovascular
system. Control mice placed on a 4% alcohol liquid diet for 14-week
developed cardiac hypertrophy and contractile defects, whereas mice
overexpressing ALDH2 exhibited a signiﬁcant attenuation of cardiac
hypertrophy and contractile dysfunction.
34 These improvements
were attributed to better calcium handling, reduction in myocardial
ﬁbrosis, reduction in protein carbonyl formation, and reduction in
apoptosis, likely through a molecular mechanism associated with
phosphorylation of apoptosis-stimulated kinase, glycogen synthase
kinase-3b, GATA4, and cAMP-response element-binding protein.
Related to alcohol-induced cardiomyopathy, overexpression of
ALDH2 can also overcome insulin resistance in the heart of chroni-
cally alcohol-fed mice via an improvement of insulin signalling.
91
This ALDH2-mediated protection mechanism also extends to the
brain as apoptosis and cerebral damages were ablated in ALDH2
overexpressing mice after 12 weeks of continuous ethanol ingestion.
92
Another approach to studying the potential consequences of
E487K mutation represented in the ALDH2*2 carrying East Asians
is the use of transgenic mice overexpressing ALDH2*2. Endo
et al.
93 created these loss-of-function ALDH2 transgenic mice by
overexpressing the E487K human form under a strong promoter. In
these mice, expression of the dominant-negative ALDH2*2 resulted
in impaired ALDH activity when using a variety of aldehydic sub-
strates. These mice also showed increased mitochondrial oxidative
stress demonstrated by an elevated level of 4-HNE–protein
adducts, a decline in mitochondria respiratory function, smaller
body size, reduced muscle mass, diminished fat content, osteopenia,
kyphosis, and smaller heart morphology.
93 Surprisingly, despite the
presence of substantial mitochondrial oxidative damage, the hearts
of these ALDH2*2 transgenic mice demonstrated a greater tolerance
to oxidative stress. This metabolic remodelling was attributed to
increased glutathione biosynthesis to compensate for the diminished
ALDH activity and the elevated oxidative stress. It should be noted
that since ALDHs are tetramers, it is possible that overexpression
of ALDH2*2 monomer inactivates not only the wild-type ALDH2,
but may also form heterotetramers and inactive other ALDH iso-
zymes (e.g. heterotetramer formation between ALDH2 and another
highly homologous ALDH1B1).
81,94 Since ALDH2*2 levels were
eight-fold higher than that of the endogenous ALDH2 wild-type
protein in the mitochondria, ALDH2*2 may therefore have pleiotro-
pic effects. This may explain why the ALDH2-null mice and mice that
express ALDH2*2 only one- to three-fold over the endogenous
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95 Whether
metabolic remodelling and cardiac adaptation exist in ALDH2*2
Asians subjects therefore remains to be determined. A better trans-
genic animal model for the study of human ALDH2*2 deﬁciency
would be the introduction, by gene targeting, of a single true
genomic E487K point mutation to replace the wild-type ALDH2*1
allele on mouse chromosome 5 via homologous recombination.
6. Conclusion
Aldehydes are commonly formed inside cells as metabolic products
(e.g. products of lipid peroxidation) or can gain access to the body
from the environment (e.g. industry pollutants and food additives).
Because aldehydes are chemically reactive moieties, forming adducts
on a variety of macromolecules, which result in impairment or inacti-
vation of these macromolecules, aldehydes catabolism is critical for
cytoprotection, in general, and for cardioprotection, in particular. A
natural cardioprotective mechanism involves a family of ALDHs and
in particular the intra-mitochondrial enzyme, ALDH2. Although
ALDH2 is constitutively active, it can be further activated by ischaemic
preconditioning (due to 1PKC-mediated phosphorylation) as well as
by small molecule activators of this enzyme, Aldas. In addition for
its role in removal of toxic aldehydes, the role of ALDH2 in nitrogly-
cerin conversion to the bioactive NO highlights the importance of this
enzyme in a variety of cardiovascular diseases. Epidemiological studies
in humans carrying an inactivating mutation in ALDH2, combined with
genetic and pharmacological studies in animal models, suggest ALDH2
as an important target for generating new treatments for heart
diseases.
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